Inozyme Pharma Stock Analysis

Inozyme Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.1. Some equities with similar Price to Book (P/B) outperform the market in the long run. Inozyme Pharma recorded a loss per share of 1.55. The entity had not issued any dividends in recent years. Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. Inozyme Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 50 people. To learn more about Inozyme Pharma call Douglas Treco at 857 330 4340 or check out https://www.inozyme.com.

Inozyme Pharma Investment Alerts

Inozyme Pharma Upcoming and Recent Events

Inozyme Largest EPS Surprises

View All Earnings Estimates

Inozyme Stock Institutional Investors

Note, although Inozyme Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Inozyme Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 91.22 M.

Inozyme Profitablity

Management Efficiency

Inozyme Pharma has return on total asset (ROA) of (0.3569) % which means that it has lost $0.3569 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7942) %, meaning that it created substantial loss on money invested by shareholders. Inozyme Pharma's management efficiency ratios could be used to measure how well Inozyme Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2025. Return On Capital Employed is likely to drop to -0.49 in 2025. At this time, Inozyme Pharma's Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 2.4 M in 2025, whereas Total Assets are likely to drop slightly above 132.8 M in 2025.

Technical Drivers

As of the 30th of January, Inozyme Pharma retains the Market Risk Adjusted Performance of (7.29), risk adjusted performance of (0.23), and Standard Deviation of 5.91. Inozyme Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Inozyme Pharma Price Movement Analysis

Inozyme Pharma Insider Trading Activities

Inozyme Pharma Outstanding Bonds

Inozyme Pharma Predictive Daily Indicators

Inozyme Pharma Forecast Models

Inozyme Pharma's time-series forecasting models are one of many Inozyme Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Inozyme Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Inozyme Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Inozyme shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Inozyme Pharma. By using and applying Inozyme Stock analysis, traders can create a robust methodology for identifying Inozyme entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Inozyme analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Inozyme analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Inozyme Pharma stock analysis indicators help investors evaluate how Inozyme Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Inozyme Pharma shares will generate the highest return on investment. By understating and applying Inozyme Pharma stock analysis, traders can identify Inozyme Pharma position entry and exit signals to maximize returns.

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.